CANF

Can-Fite BioPharma Ltd. ADR (CANF) | Rumor.io

Can-Fite BioPharma

CANF

Attention (50-day avg)0%

Attention rank (50-day avg)#1,857

Bullish sentiment (50-day avg)35%

Price to earnings ratio-0.2

Market capitalization4.8M

Earnings per share-4.65

Dividend yield (TTM)—

Revenue (annual)405K

Net income (annual)-9.8M

Social

What share of all stock conversation is about CANF?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Sep 2

Can-Fite BioPharma Ltd. reports longer-than-anticipated overall survival in its pivotal Phase III liver cancer trial, prompting an accelerated interim analysis.
The stock is up ~40% premarket on massive relative volume, with significant potential dilution from ~1.59M warrants with a $5 exercise price.
Can-Fite's Phase III study remains blinded, but the news has sparked a strong momentum play, with some analysts expecting the stock to reach $6-$8.

Generated by AI

Sentiment

Of the messages about CANF that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	30.65% -69.35	69.98% -6.22
Bearish	—	—	69.35% +69.35	30.02% +6.22

Bullish· Sep 2

Can-Fite BioPharma Ltd. ($CANF) reported longer-than-anticipated overall survival in its ongoing pivotal Phase III liver cancer study, which could lead to a significant increase in the company's value.
The study's positive results, combined with a low float of 4.65M shares, create a strong potential for a squeeze, with some analysts predicting a rapid and violent move to $5.00 or higher.
With a significant portion of shares shorted, the company's phase 3 news could lead to a 50% or higher upside in the near term, making it an attractive investment opportunity for those who have been patient and are now ready to capitalize on the potential gains.

Bearish· Sep 2

A large at-the-market offering was recently filed, which may be a trap for retail investors to buy into the dilution, causing a decline in the stock's price.
The asset's price action is suspicious, with a possible design to lure investors in before diluting the stock, creating a "spider web" effect.
The company's stock is expected to experience significant dilution, with the price potentially moving lower, prompting warnings to investors to "run away as fast as you can."

Generated by AI

Topics

Of the messages about CANF that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	62.5%	29.74%
Technical Analysis	—	—	37.5%	9.72%
Analysts	—	—	0%	31.88%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	28.66%

Announcements· Jun 26

Can-Fite BioPharma's anti-obesity patent, Namodenoson, has been approved in Japan, expanding its international intellectual property.
The patent allows the use of Namodenoson for fat loss and obesity treatment, reinforcing the company's global IP for its oral anti-obesity program.
The Japan Patent Office's allowance strengthens Can-Fite's long-term obesity strategy and bolsters potential partnerships in the expected $60 billion obesity treatment market by 2030.

Technical Analysis· Mar 4

CANF is due for another run if this strength holds, with buyers defending pullbacks and the trend still intact.
CANF is trending up after strong relative strength versus peers, with news out on expansion plans and interest in the tape.
CANF has a large move on the phase 2a news in premarket, with high volatility and potential for a downtrend break.

Generated by AI

Community

Of the messages about CANF, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	34.68%	28.41%
Newcomers	—	—	65.32%	71.59%

Regulars· Sep 2

Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study, indicating positive results for the company's treatment.
The asset is expected to move rapidly and violently, with a target of $5.00, following the release of excellent Phase 3 results for its liver cancer treatment.
The company's recent $100M shelf is expected to be used at the open, setting the stage for a potentially significant price movement.

Newcomers· Sep 2

Newcomers are focused on Can-Fite BioPharma Ltd.'s recent Phase III liver cancer trial, which reported longer-than-anticipated overall survival.
Investors are discussing the potential for a squeeze, with some users expressing concerns about the company's warrants and potential dilution.
The stock's price action is being driven by a large AT THE MARKET OFFERING, with some users speculating that the price movement may be designed to encourage buying ahead of the offering.

Generated by AI

Patient Experienced Resolution of Ascites, Regression of Esophageal Varices and Remained Clinically Stable for Approximately 28 Months Prior to Successful Liver Transplantation Ramat Gan, Israel, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced the publication of a peer-reviewed case report

21d agoYahoo Finance

Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

RAMAT GAN, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced clinical updates and financial results for H1 2026. Advances in Clinical Programs Pancreatic Cancer Phase 2a study evaluating Namodenoson in patients with advanced pancreatic ductal adenocarcinoma achieved its primary safety endpoint and d

21d agoYahoo Finance

Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study

27d agoYahoo Finance

Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds

RAMAT GAN, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) (“Can-Fite” or the “Company”), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,591,738 American Depositary Shares (ADSs), having an exercise

27d agoYahoo Finance

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

27d agoBenzinga

Also Discussed

Investors talking about CANF also mention

#	Name	Attention
1	XOMA CorporationXOMA	0%0
2	Energy Recovery, Inc.ERII	0%new
3	BLPH - Bellerophon Therapeutics, Inc.	——
4	GENE - Genetic Technologies Limited	——
5	Edap Tms S.A.EDAP	0%0
6	BioLine RX LtdBLRX	0%0
7	AEZS - Aeterna Zentaris Inc.	——
8	XTL Biopharmaceuticals Ltd. - ADRXTLB	0%0
9	Net Element IncNETE	0%0
10	NTBL - Notable Labs, Ltd.	——

Can-Fite BioPharma Ltd. ADR

Healthcare
Biotechnology

Can-Fite BioPharma Ltd. ADR is a clinical-stage biopharmaceutical company focused on developing orally administered small-molecule therapies for cancer, liver diseases, inflammatory conditions, and erectile dysfunction. The company’s current pipeline centers on drug candidates designed to modulate the A3 adenosine receptor, a biological target associated with inflammatory and cancer-related pathways. Its product portfolio includes programs such as Piclidenoson, Namodenoson, and CF602, reflecting a research model built around targeted treatments for serious unmet medical needs. Can-Fite BioPharma also works on cannabinoid-based programs and biomarker tools that support patient selection and therapeutic development. Headquartered in Israel, the company operates as a specialist drug developer within the global biotechnology sector, where it plays a role in advancing precision-oriented therapies from clinical research toward potential medical use.

Website

Location

26 Ben Gurion Street

Ramat Gan, 5257346

Israel

Social

What share of all stock conversation is about CANF?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Sep 2

Can-Fite BioPharma Ltd. reports longer-than-anticipated overall survival in its pivotal Phase III liver cancer trial, prompting an accelerated interim analysis.
The stock is up ~40% premarket on massive relative volume, with significant potential dilution from ~1.59M warrants with a $5 exercise price.
Can-Fite's Phase III study remains blinded, but the news has sparked a strong momentum play, with some analysts expecting the stock to reach $6-$8.

Generated by AI

Sentiment

Of the messages about CANF that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	30.65% -69.35	69.98% -6.22
Bearish	—	—	69.35% +69.35	30.02% +6.22

Bullish· Sep 2

Can-Fite BioPharma Ltd. ($CANF) reported longer-than-anticipated overall survival in its ongoing pivotal Phase III liver cancer study, which could lead to a significant increase in the company's value.
The study's positive results, combined with a low float of 4.65M shares, create a strong potential for a squeeze, with some analysts predicting a rapid and violent move to $5.00 or higher.
With a significant portion of shares shorted, the company's phase 3 news could lead to a 50% or higher upside in the near term, making it an attractive investment opportunity for those who have been patient and are now ready to capitalize on the potential gains.

Bearish· Sep 2

A large at-the-market offering was recently filed, which may be a trap for retail investors to buy into the dilution, causing a decline in the stock's price.
The asset's price action is suspicious, with a possible design to lure investors in before diluting the stock, creating a "spider web" effect.
The company's stock is expected to experience significant dilution, with the price potentially moving lower, prompting warnings to investors to "run away as fast as you can."

Generated by AI

Topics

Of the messages about CANF that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	62.5%	29.74%
Technical Analysis	—	—	37.5%	9.72%
Analysts	—	—	0%	31.88%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	28.66%

Announcements· Jun 26

Can-Fite BioPharma's anti-obesity patent, Namodenoson, has been approved in Japan, expanding its international intellectual property.
The patent allows the use of Namodenoson for fat loss and obesity treatment, reinforcing the company's global IP for its oral anti-obesity program.
The Japan Patent Office's allowance strengthens Can-Fite's long-term obesity strategy and bolsters potential partnerships in the expected $60 billion obesity treatment market by 2030.

Technical Analysis· Mar 4

CANF is due for another run if this strength holds, with buyers defending pullbacks and the trend still intact.
CANF is trending up after strong relative strength versus peers, with news out on expansion plans and interest in the tape.
CANF has a large move on the phase 2a news in premarket, with high volatility and potential for a downtrend break.

Generated by AI

Community

Of the messages about CANF, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	34.68%	28.41%
Newcomers	—	—	65.32%	71.59%

Regulars· Sep 2

Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study, indicating positive results for the company's treatment.
The asset is expected to move rapidly and violently, with a target of $5.00, following the release of excellent Phase 3 results for its liver cancer treatment.
The company's recent $100M shelf is expected to be used at the open, setting the stage for a potentially significant price movement.

Newcomers· Sep 2

Newcomers are focused on Can-Fite BioPharma Ltd.'s recent Phase III liver cancer trial, which reported longer-than-anticipated overall survival.
Investors are discussing the potential for a squeeze, with some users expressing concerns about the company's warrants and potential dilution.
The stock's price action is being driven by a large AT THE MARKET OFFERING, with some users speculating that the price movement may be designed to encourage buying ahead of the offering.

Generated by AI

Can-Fite BioPharma

Social

Sep 2

Bullish· Sep 2

Bearish· Sep 2

Announcements· Jun 26

Technical Analysis· Mar 4

Regulars· Sep 2

Newcomers· Sep 2

H.C. Wainwright reiterates Can-Fite BioPharma stock rating at buy

Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation

Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study

Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Also Discussed

Can-Fite BioPharma Ltd. ADR

Company Information

Location

H.C. Wainwright reiterates Can-Fite BioPharma stock rating at buy

Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation

Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study

Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Also Discussed

Social

Sep 2

Bullish· Sep 2

Bearish· Sep 2

Announcements· Jun 26

Technical Analysis· Mar 4

Regulars· Sep 2

Newcomers· Sep 2